scholarly journals Type 2 diabetes and risk of hospital admission or death for chronic liver diseases

2016 ◽  
Vol 64 (6) ◽  
pp. 1358-1364 ◽  
Author(s):  
Sarah H. Wild ◽  
Joanne R. Morling ◽  
David A. McAllister ◽  
Jan Kerssens ◽  
Colin Fischbacher ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Hospital Admission ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases

scholarly journals Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases

2019 ◽  
Vol 8 (6) ◽  
pp. 3206-3215 ◽  
Author(s):  
Chen‐Pin Wang ◽  
John Kuhn ◽  
Dimpy P. Shah ◽  
Susanne Schmidt ◽  
Yui‐Wing F. Lam ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Type 2 Diabetes ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases

scholarly journals Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC

2021 ◽  
Vol 22 (9) ◽  
pp. 4495
Author(s):  
Hyunmi Kim ◽  
Da Som Lee ◽  
Tae Hyeon An ◽  
Hyun-Ju Park ◽  
Won Kon Kim ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Liver Failure ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Biological Processes ◽  
Chronic Liver Diseases ◽  
Nonalcoholic Fatty Liver ◽  
Diabetes And Obesity

Liver disease is the spectrum of liver damage ranging from simple steatosis called as nonalcoholic fatty liver disease (NAFLD) to hepatocellular carcinoma (HCC). Clinically, NAFLD and type 2 diabetes coexist. Type 2 diabetes contributes to biological processes driving the severity of NAFLD, the primary cause for development of chronic liver diseases. In the last 20 years, the rate of non-viral NAFLD/NASH-derived HCC has been increasing rapidly. As there are currently no suitable drugs for treatment of NAFLD and NASH, a class of thiazolidinediones (TZDs) drugs for the treatment of type 2 diabetes is sometimes used to improve liver failure despite the risk of side effects. Therefore, diagnosis, prevention, and treatment of the development and progression of NAFLD and NASH are important issues. In this review, we will discuss the pathogenesis of NAFLD/NASH and NAFLD/NASH-derived HCC and the current promising pharmacological therapies of NAFLD/NASH. Further, we will provide insights into “adipose-derived adipokines” and “liver-derived hepatokines” as diagnostic and therapeutic targets from NAFLD to HCC.

Helicobacter infection in patients with HCV-chronic liver diseases

2001 ◽  
Vol 120 (5) ◽  
pp. A725-A725
Author(s):  
M DORE ◽  
G REALDI ◽  
D MURA ◽  
D GRAHAM ◽  
A SEPULVEDA
Keyword(s):  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases

TRAF1-C5as risk locus for increased hepatic fibrosis in chronic liver diseases

2008 ◽  
Vol 46 (09) ◽  
Author(s):  
F Grünhage ◽  
A Höblinger ◽  
S Schwartz ◽  
T Sauerbruch ◽  
F Lammert
Keyword(s):  
Hepatic Fibrosis ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Risk Locus
Sign in / Sign up

Export Citation Format

Share Document